ebomi
Colour theme
Sign in
Insider · CIK 0001425738

Redmile Group, LLC

CIK 0001425738 Name as filed on the most recent filing

Filed as Redmile Group, LLC (46)

103 transaction lines · from 46 filings · filed 2015-08-10 to 2026-08-07 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-08-06 P, Open-market purchase Attovia Therapeutics, Inc.ATTO 2 lines 10,200,000, acquired Open Form 4 filing 0001104659-26-092867
2026-04-02 S, Open-market sale ADC Therapeutics SAADCT 2 lines 16,932,746, disposed Open Form 4 filing 0001104659-26-039359
2026-04-01 S, Open-market sale ADC Therapeutics SAADCT 2 lines 1,260,440, disposed Open Form 4 filing 0001104659-26-039359
2026-03-31 S, Open-market sale ADC Therapeutics SAADCT 2 lines 1,443,154, disposed Open Form 4 filing 0001104659-26-039359
2024-12-20 S, Open-market sale Fate Therapeutics IncFATE 573,943, disposed Open Form 4 filing 0001104659-24-131794
2024-12-20 P, Open-market purchase Fate Therapeutics IncFATE 668,580, acquired Open Form 4 filing 0001104659-24-131794
2024-12-11 P, Open-market purchase ADC Therapeutics SAADCT 4 lines 609,000, acquired Open Form 4 filing 0001104659-24-128575
2024-12-04 S, Open-market sale Shattuck Labs, Inc.STTK 166,714, disposed Open Form 4 filing 0001104659-24-126421
2024-12-04 P, Open-market purchase Shattuck Labs, Inc.STTK 166,714, acquired Open Form 4 filing 0001104659-24-126421
2024-12-04 S, Open-market sale ADC Therapeutics SAADCT 52,479, disposed Open Form 4 filing 0001104659-24-126422
2024-07-01 P, Open-market purchase ADC Therapeutics SAADCT 2 lines 2,248,000, acquired Open Form 4 filing 0001104659-24-077865
2024-03-01 P, Open-market purchase Absci CorpABSI 999,999, acquired Open Form 4 filing 0001104659-24-031215
2023-12-26 P, Open-market purchase Fate Therapeutics IncFATE 166,024, acquired Open Form 4 filing 0001104659-23-130203
2023-11-20 P, Open-market purchase Augmedix, Inc.AUGX 2 lines 6,000,000, acquired Open Form 4 filing 0001104659-23-120752
2023-06-29 S, Open-market sale IGM Biosciences, Inc.IGMS 757,585, disposed Open Form 4 filing 0001104659-23-077730
2023-06-29 P, Open-market purchase IGM Biosciences, Inc.IGMS 757,585, acquired Open Form 4 filing 0001104659-23-077730
2023-04-21 P, Open-market purchase Fate Therapeutics IncFATE 1,586,029, acquired Open Form 4 filing 0001104659-23-048557
2023-04-20 P, Open-market purchase Fate Therapeutics IncFATE 119,800, acquired Open Form 4 filing 0001104659-23-048557
2023-04-14 S, Open-market sale Fate Therapeutics IncFATE 1,765,660, disposed Open Form 4 filing 0001104659-23-046353
2023-04-14 P, Open-market purchase Fate Therapeutics IncFATE 154,200, acquired Open Form 4 filing 0001104659-23-046353
2022-10-13 P, Open-market purchase Zymeworks Inc.ZYME 153,435, acquired Open Form 4 filing 0001104659-22-109481
2021-11-02 P, Open-market purchase Entrada Therapeutics, Inc.TRDA 20,000,000, acquired Open Form 4 filing 0001104659-21-134623
2021-10-28 P, Open-market purchase Augmedix, Inc.AUGX 6,500,000, acquired Open Form 4 filing 0001104659-23-048555
2021-10-28 P, Open-market purchase Augmedix, Inc.AUGX 6,500,000, acquired Open Form 4 filing 0001104659-21-132515
2021-08-10 P, Open-market purchase Adagio Therapeutics, Inc.ADGI 24,990,000, acquired Open Form 4 filing 0001104659-21-104447
2021-07-26 P, Open-market purchase Absci CorpABSI 30,000,000, acquired Open Form 4 filing 0001104659-21-097155
2021-06-21 P, Open-market purchase Verve Therapeutics, Inc.VERV 19,950,000, acquired Open Form 4 filing 0001104659-21-084633
2021-01-08 P, Open-market purchase Fate Therapeutics IncFATE 27,999,968, acquired Open Form 4 filing 0001104659-21-003446
2020-12-28 S, Open-market sale Aprea Therapeutics, Inc.APRE 2 lines 2,791,290, disposed Open Form 4 filing 0001104659-21-023991
2020-10-14 P, Open-market purchase Shattuck Labs, Inc.STTK 6 lines 59,669,343, acquired Open Form 4 filing 0001104659-20-115357
2020-10-05 P, Open-market purchase Augmedix, Inc.AUGX 15,000,000, acquired Open Form 4 filing 0001104659-20-113147
2020-09-09 P, Open-market purchase IGM Biosciences, Inc.IGMS 2 lines 1,222,335, acquired Open Form 4 filing 0001104659-20-103551
2020-09-08 P, Open-market purchase IGM Biosciences, Inc.IGMS 2,351,504, acquired Open Form 4 filing 0001104659-20-103551
2020-09-04 P, Open-market purchase IGM Biosciences, Inc.IGMS 3,742,186, acquired Open Form 4 filing 0001104659-20-103551

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Redmile Group, LLC, insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001425738

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.